[1] STRIJKER M,BELKOUZ A,YAN DER GEEST L G,et al. Treatment and survival of resected and unresected distal cholangiocarcinoma:a nationwide study[J].Acta Oncol,2019,58(7):1048-1055. [2] 陈顺,吴子龙,王方明,等. 腹腔镜与开腹胰十二指肠切除术治疗远端胆管癌疗效分析[J].中华普通外科杂志,2021,36(9):653-657. [3] 於雷,代智,王征,等. 淋巴结转移对肝内胆管细胞癌患者预后的影响及临床相关因素研究[J].中国癌症杂志,2020,30(9):694-700. [4] QIAN Z,HU W,LV Z,et al. PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma[J].Clin Res Hepatol Gas,2020,44(2):162-173. [5] 中国抗癌协会. 远端胆管癌规范化诊治专家共识(2017)[J] .中华肝胆外科杂志,2018,24(1):1-8. [6] 段小辉,毛先海,蒋波,等. 腹腔镜胰十二指肠切除术治疗远端胆管癌的临床疗效[J].中华消化外科杂志,2018,17(3):304-309. [7] CHIN K M,DI MARTINO M,SYN N,et al. Re-appraising the role of lymph node status in predicting survival in resected distal cholangiocarcinoma-A meta-analysis and systematic review[J].Eur J Surg Oncol,2021,47(6):1267-1277. [8] NAKANISHI Y,OKAMURA K,TSUNCHIKAWA T,et al. Time to recurrence after surgical resection and survival after recurrence among patients with perihilar and distal cholangiocarcinomas[J].Ann Surg Oncol,2020,27(11):4171-4180. [9] MONTAL R,SIA D,MONTIRONI C,et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma[J].J Hepatol,2020,73(2):315-327. [10] HOSHIMOTO S,HISINUMA S,SHIRAKAWA H,et al. Association of preoperative platelet-to-lymphocyte ratio with poor outcome in patients with distal Cholangiocarcinoma[J].Oncology,2019,96(6):290-298. [11] JIANG T,LYU S C,ZHOU L,et al. Carbohydrate antigen 19-9 as a novel prognostic biomarker in distal cholangiocarcinoma[J].World J Gastrointest Surg,2021,13(9):1025-1038. [12] BOLM L,PETROVA E,WEITZ J,et al. Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma[J].HPB (Oxford),2019,21(11):1513-1519. [13] LEE T,TENG T Z J,SHELAT V G. Carbohydrate antigen 19-9 tumor marker:Past,present,and future[J].World J Gastrointest Surg,2020,12(12):468-490. [14] TAKIHATA Y,EINAMA T,KOBAYASHI K,et al. Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma[J].Oncol Lett,2021,21(5):414-420. [15] 韩超,靳龙洋,翟天宇,等. 术前肿瘤标志物检测对肝内胆管细胞癌淋巴结转移的预测价值[J].中华消化外科杂志,2017,16(5):503-507.
2022, Vol. 39 
